Amifostine trihydrate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

氨磷汀是第一种批准的放射防护化合物，用于降低顺铂治疗引起的肾脏问题的风险。

Amifostine is the first approved radioprotective drug, used to decrease the risk of kidney problems caused by treatment with cisplatin.

Amifostine (0.78125-100?μM, 24 h)trihydrate reduces tert-Butyl hydroperoxide (TBHP)-induced cell damage in a dose-dependent manner and significantly reduces H9c2 cells apoptosis at a concentration of 100 μM.

Amifostine (i.v., 400 mg/kg, 4 h) trihydrate has a protective effect against myocardial I/R injury in male C57BL/6 mice. Animal Model:Male C57BL/6 mice with myocardial I/R injury Dosage:400 mg/kg Administration: Intravenous injection; 4 hours Result:Attenuated cardiomyocyte apoptosis and reduced the production of I/R-induced ROS.Significantly reduced the expression of cleaved caspase 3 and Bax whileenhanced the expression of SOD1, SOD2 and Bcl2.Significantly increased SOD activity and reduced MDA levels.

——

Others

Other Targets

Others

Others-Field

——

112901-68-5

268.27

C5H15N2O3PS·3H2O

>98% (HPLC)

In Vitro:?H2O : 125 mg/mL (465.95 mM)

O.O.O.NCCCNCCSP(O)(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years